Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells

Abstract Background Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a common, yet highly efficient, cellular immunotherapy for lymphoma. However, many recent studies have reported on its cardiovascular (CV) toxicity. This study analyzes the cardiotoxicity of CD19 CAR T cell therapy in th...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yang Liu, Xiaoshuang Yuan, Xu Yang, Bo Yang, Guangyang Liu, Xiao Xu, Sanbin Wang, Zhixu He, Feiqing Wang, Yanju Li
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-01-01
Colecção:	Journal of Translational Medicine
Assuntos:	CD19 Chimeric antigen receptor T cells CAR-T therapy Lymphoma Cardiovascular toxicity
Acesso em linha:	https://doi.org/10.1186/s12967-024-06035-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!